Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GFL Environmental Inc. Subordinate voting shares no par value (GFL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

GFL Environmental Inc. Subordinate voting shares no par valueTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

GFL Environmental Inc. Subordinate voting shares no par value vs State Street SPDR S&P Biotech ETF — how do they compare? GFL Environmental Inc. Subordinate voting shares no par value trades at $42.2 (market cap $18.46B), while State Street SPDR S&P Biotech ETF trades at $149.99 (market cap $10.08B). The key difference: GFL Environmental Inc. Subordinate voting shares no par value is the larger of the two by market cap, and GFL Environmental Inc. Subordinate voting shares no par value pays a 0.16% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GFL Environmental Inc. Subordinate voting shares no par value for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.

GFLXBI
Market Cap
$18.46B$10.08B
Volume
2,438,3539,534,635
Sector
IndustrialsBroad Market / Factor
52-Week High
$46.51$169.55
52-Week Low
$33.54$104.99
Typical Hold Time
0 Days37 Days
Enterprise Value
$25.43B—
Dividend Yield
0.16%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GFL Environmental Inc. Subordinate voting shares no par value

No Aura AI signal available yet.

State Street SPDR S&P Biotech ETF

XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.

Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GFL
100% Buy0% Sell
Avg holding period · 0 Days
XBI
100% Buy0% Sell
Avg holding period · 37 Days

About GFL Environmental Inc. Subordinate voting shares no par value

GFL Environmental provides environmental services across Canada and the United States. Its operations include solid waste management and other waste and environmental solutions.

Read more on GFL →

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI →